Skip to main content
SpringerLink
Log in
Book cover

Bacterial Infections of Humans pp 849–877Cite as

Tuberculosis

  • Chapter
  • First Online:

  • 2989 Accesses

Tuberculosis is a contagious disease spread through the air in tiny droplet nuclei. Propelled into the air by the cough, sneeze, or speech of a person sick with pulmonary tuberculosis, Mycobacterium tuberculosis bacilli can stay suspended for prolonged periods of time, ready to be inhaled by others sharing the same airspace. M. tuberculosis usually results in latent infection controlled by cellular immunity and may later progress to active disease. Though primarily a pulmonary disease, tuberculosis can affect many organs, and continues to be a major cause of illness, disability, and premature death throughout the world. Tuberculosis has been curable for more than 50 years; a standard drug regimen of specific antibiotics for a minimum of 6 months is required.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Notes

  1. 1.

    George W. Comstock is deceased

References

  1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. Aug 18 1999;282(7):677–686.

    Google Scholar 

  2. Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA. Jun 8 2005;293(22):2767–2775.

    Google Scholar 

  3. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. Jun 11 1998;393(6685):537–544.

    Google Scholar 

  4. Dubos R, Dubos J. The White Plague, Tuberculosis, Man and Society. Boston, MA: Little, Brown and Company; 1952.

    Google Scholar 

  5. Heifets LB, Good RC. Current Laboratory Methods for the Diagnosis of Tuberculosis. Washington, DC: ASM Press; 1994.

    Google Scholar 

  6. Keiger D. Why metaphor matters. Johns Hopkins Mag. 1998;50: 12–18.

    Google Scholar 

  7. Institute of Medicine. Ending Neglect: The Elimination of Tuberculosis in the United States. Washington, DC: National Academy of Sciences; 2000.

    Google Scholar 

  8. CDC. Reported Tuberculosis in the United States, 2003. Atlanta, GA: US Department of Health and Human Services; 2004.

    Google Scholar 

  9. Lowell AM, Edwards, LB, Palmer, CE. Tuberculosis. Cambridge, MA: Harvard University Press; 1969.

    Google Scholar 

  10. Lowell AM. Tuberculosis in the World: HEW Publication Number (CDC) 76-8317. Washington, DC: US Government Printing Office; 1976.

    Google Scholar 

  11. Styblo K, Rouillon A. Estimations concerning the world incidence of positive pulmonary tuberculosis from sputum smears. Unreliability of official totals reported on tuberculosis. Bull Int Union Tuberc. Sep–Dec 1981;56(3–4):118–126.

    Google Scholar 

  12. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. May 12 2003;163(9):1009–1021.

    Google Scholar 

  13. Ansari NA, Kombe AH, Kenyon TA, et al. Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997–1998. Int J Tuberc Lung Dis. Jan 2002;6(1): 55–63.

    Google Scholar 

  14. Rana FS, Hawken MP, Mwachari C, et al. Autopsy study of HIV-1-positive and HIV-1-negative adult medical patients in Nairobi, Kenya. J Acquir Immune Defic Syndr. May 1 2000;24(1):23–29.

    Google Scholar 

  15. WHO. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2004. Geneva: World Health Organization; 2004.

    Google Scholar 

  16. CDC. Case definitions of infectious conditions under public health surveillance. MMWR Morb Mortal Wkly Rep. 1997;46(RR10): 40–41.

    Google Scholar 

  17. Armstrong DB. Four years of the Framingham demonstration. Am Rev Tuberc. 1921;4:908–919.

    Google Scholar 

  18. de Abreau M, de Paula A. Roentgenfotografia. Rio de Janeiro: Livraria Ateneu; 1940.

    Google Scholar 

  19. Jarman TF. A follow-up tuberculin survey in the Rhondda Fach. Br Med J. 1955;2:1235–1239.

    Article  PubMed  CAS  Google Scholar 

  20. Kaplan GJ, Fraser RI, Comstock GW. Tuberculosis in Alaska, 1970. The continued decline of the tuberculosis epidemic. Am Rev Respir Dis. Jun 1972;105(6):920–926.

    Google Scholar 

  21. Sartwell PE, Moseley CH, Long ER. Tuberculosis in the German population, United States Zone of Germany. Am Rev Tuberc. 1949;59:481–493.

    PubMed  CAS  Google Scholar 

  22. Magnus K. Epidemiological basis of tuberculosis eradication. 6. Tuberculin sensitivity after human and bovine infection. Bull World Health Organ. 1967;36(5):719–731.

    PubMed  CAS  Google Scholar 

  23. Edwards LB, Acquaviva FA, Livesay VT. Identification of tuberculous infected. Dual tests and density of reaction. Am Rev Respir Dis. Dec 1973;108(6):1334–1339.

    Google Scholar 

  24. Edwards LB, Acquaviva FA, Livesay VT, Cross FW, Palmer CE. An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States. Am Rev Respir Dis. Apr 1969;99(4):Suppl: 1–132.

    Google Scholar 

  25. Edwards LB, Comstock GW, Palmer CE. Contributions of northern populations to the understanding of tuberculin sensitivity. Arch Environ Health. Oct 1968;17(4):507–516.

    Google Scholar 

  26. Edwards LB, Livesay VT, Acquaviva FA, Palmer CE. Height, weight, tuberculous infection, and tuberculous disease. Arch Environ Health. Jan 1971;22(1):106–112.

    Google Scholar 

  27. Palomino JC. Nonconventional and new methods in the diagnosis of tuberculosis: feasibility and applicability in the field. Eur Respir J. Aug 2005;26(2):339–350.

    Google Scholar 

  28. Kubica GP. Clinical Microbiology. New York: Marcel Dekker; 1984.

    Google Scholar 

  29. Brett JL, Humble MW. The BACTEC TB system in the laboratory diagnosis of mycobacterial infection. N Z Med J. Oct 9 1991;104(921):422–424.

    Google Scholar 

  30. Palomino JC, Traore H, Fissette K, Portaels F. Evaluation of Mycobacteria Growth Indicator Tube (MGIT) for drug susceptibility testing of Mycobacterium tuberculosis. Int J Tuberc Lung Dis. Apr 1999;3(4):344–348.

    Google Scholar 

  31. Berkel GM, Cobelens FG, de Vries G, Draayer-Jansen IW, Borgdorff MW. Tuberculin skin test: estimation of positive and negative predictive values from routine data. Int J Tuberc Lung Dis. Mar 2005;9(3):310–316.

    Google Scholar 

  32. Enarson DA. Use of the tuberculin skin test in children. Paediatr Respir Rev. 2004;5 Suppl A:S135–S137.

    Article  PubMed  Google Scholar 

  33. Nolan CM, Goldberg SV. Analysis of the frequency distribution of tuberculin skin test readings: a tool for the assessment of group contact investigations. Int J Tuberc Lung Dis. Dec 2003;7(12 Suppl 3):S439–S445.

    Google Scholar 

  34. Diagnostic standards and classification of tuberculosis. Am Rev Respir Dis. Apr 1991;143(4 Pt 1):895–896.

    Google Scholar 

  35. Nissen Meyer S, Hougen A, Edwards PQ. Experimental error in the determination of tuberculin sensitivity. Public Health Rep. 1951;63:561–569.

    Google Scholar 

  36. CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. Jun 9 2000;49(RR-6):1–51.

    Google Scholar 

  37. Gordin FM, Perez-Stable EJ, Flaherty D, et al. Evaluation of a third sequential tuberculin skin test in a chronic care population. Am Rev Respir Dis. Jan 1988;137(1):153–157.

    Google Scholar 

  38. Snider DE, Jr., Cauthen GM. Tuberculin skin testing of hospital employees: infection, "boosting," and two-step testing. Am J Infect Control. Dec 1984;12(6):305–311.

    Google Scholar 

  39. Mazurek GH, Villarino ME. Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. Centers for Disease Control and Prevention. MMWR Recomm Rep. Jan 31 2003;52(RR-2):15–18.

    Google Scholar 

  40. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep. Dec 16 2005;54(RR-15):49–55.

    Google Scholar 

  41. Dheda K, Lalvani A, Miller RF, et al. Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. Aids. Nov 18 2005;19(17): 2038–2041.

    Google Scholar 

  42. Meier T, Eulenbruch HP, Wrighton-Smith P, Enders G, Regnath T. Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice. Eur J Clin Microbiol Infect Dis. Aug 2005;24(8):529–536.

    Google Scholar 

  43. Ferrara G, Losi M, D’Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet. Apr 22 2006;367(9519):1328–1334.

    Google Scholar 

  44. Kimura M, Converse PJ, Astemborski J, et al. Comparison between a whole blood interferon-gamma release assay and tuberculin skin testing for the detection of tuberculosis infection among patients at risk for tuberculosis exposure. J Infect Dis. May 1999;179(5):1297–1300.

    Google Scholar 

  45. De Voss JJ, Rutter K, Schroeder BG, Su H, Zhu Y, Barry CE, 3rd. The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages. Proc Natl Acad Sci U S A. Feb 1 2000;97(3):1252–1257.

    Google Scholar 

  46. Riley RL, Knight M, Middlebrook G. Ultraviolet susceptibility of BCG and virulent tubercle bacilli. Am Rev Respir Dis. Apr 1976;113(4):413–418.

    Google Scholar 

  47. Fennelly KP, Martyny JW, Fulton KE, Orme IM, Cave DM, Heifets LB. Cough-generated aerosols of Mycobacterium tuberculosis: a new method to study infectiousness. Am J Respir Crit Care Med. Mar 1 2004;169(5):604–609.

    Google Scholar 

  48. Nardell EA. Catching droplet nuclei: toward a better understanding of tuberculosis transmission. Am J Respir Crit Care Med. Mar 1 2004;169(5):553–554.

    Google Scholar 

  49. Nyboe J. Interpretation of tuberculosis infection age curves. Bull. WHO. 1957;17:319–339.

    PubMed  CAS  Google Scholar 

  50. Sutherland I, Fayers PM. The association of the risk of tuberculous infection with age. Bull Int Union Tuberc. 1975;50(1):70–81.

    PubMed  CAS  Google Scholar 

  51. Clark M, Vynnycky E. The use of maximum likelihood methods to estimate the risk of tuberculous infection and disease in a Canadian First Nations population. Int J Epidemiol. Jun 2004;33(3):477–484.

    Google Scholar 

  52. Tuberculosis in developing countries. MMWR Wkly. August 24, 1990;39(33):567–569.

    Google Scholar 

  53. Yu MC, Suo J, Huang C, Bai KJ, Lin TP, Luh KT. Annual risk of tuberculous infection in Taiwan, 1996–1998. J Formos Med Assoc. Jul 1999;98(7):496–499.

    Google Scholar 

  54. Kumar N, Baral DD, Tamrakar S. Tuberculin survey in government high school of Dharan municipality. JNMA J Nepal Med Assoc. Jan–Mar 2005;44(157):13–17.

    Google Scholar 

  55. Chakraborty AK. Epidemiology of tuberculosis: current status in India. Indian J Med Res. Oct 2004;120(4):248–276.

    Google Scholar 

  56. WHO. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2004. Geneva: World Health Organization; 2005.

    Google Scholar 

  57. Dye C. Global epidemiology of tuberculosis. Lancet. Mar 18 2006;367(9514):938–940.

    Google Scholar 

  58. Haddad MB, Wilson TW, Ijaz K, Marks SM, Moore M. Tuberculosis and homelessness in the United States, 1994–2003. JAMA. Jun 8 2005;293(22):2762–2766.

    Google Scholar 

  59. Valin N, Antoun F, Chouaid C, et al. Outbreak of tuberculosis in a migrants’ shelter, Paris, France, 2002. Int J Tuberc Lung Dis. May 2005;9(5):528–533.

    Google Scholar 

  60. Doyle YG, Graves P, Rayner C, Gerada C, Wakefield D. Factors contributing to the cause of a community outbreak of tuberculosis. J Public Health (Oxf). Jun 2004;26(2):193–196.

    Google Scholar 

  61. Phillips L, Carlile J, Smith D. Epidemiology of a tuberculosis outbreak in a rural Missouri high school. Pediatrics. Jun 2004;113(6):e514–e519.

    Google Scholar 

  62. Valway SE, Sanchez MP, Shinnick TF, et al. An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. N Engl J Med. Mar 5 1998;338(10):633–639.

    Google Scholar 

  63. Comstock GW. Frost revisited: the modern epidemiology of tuberculosis. Am J Epidemiol. May 1975;101(5):363–382.

    Google Scholar 

  64. Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwahara RJ, Wilce MA, Nguyen CH. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med. Dec 2000;162(6): 2033–2038.

    Google Scholar 

  65. Elliott AM, Hayes RJ, Halwiindi B, et al. The impact of HIV on infectiousness of pulmonary tuberculosis: a community study in Zambia. AIDS. Jul 1993;7(7):981–987.

    Google Scholar 

  66. Gessner BD, Weiss NS, Nolan CM. Risk factors for pediatric tuberculosis infection and disease after household exposure to adult index cases in Alaska. J Pediatr. Mar 1998;132(3 Pt 1):509–513.

    Google Scholar 

  67. Grzybowski S, Barnett GD, Styblo K. Contacts of cases of active pulmonary tuberculosis. Bull Int Union Tuberc. 1975;50(1): 90–106.

    PubMed  CAS  Google Scholar 

  68. Daniels M, Ridehalgh F, Springett VH. Tuberculosis in Young Adults: Report on the Prophit Tuberculosis Survey, 1936–1944. London: H.K. Lewis; 1948.

    Google Scholar 

  69. Desjardin LE, Perkins MD, Wolski K, et al. Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy. Am J Respir Crit Care Med. Jul 1999;160(1):203–210.

    Google Scholar 

  70. Kamat SR, Dawson JJ, Devadatta S, et al. A controlled study of the influence of segregation of tuberculous patients for one year on the attack rate of tuberculosis in a 5-year period in close family contacts in South India. Bull World Health Organ. 1966;34(4):517–532.

    PubMed  CAS  Google Scholar 

  71. Bouvet E, Casalino E, Mendoza-Sassi G, et al. A nosocomial outbreak of multidrug-resistant Mycobacterium bovis among HIV-infected patients. A case–control study. AIDS. Nov 1993;7(11): 1453–1460.

    Google Scholar 

  72. MMWR. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons—Florida and New York, 1988–1991. Morb Mortal Wkly Rep. Aug 30 1991;40(34): 585–591.

    Google Scholar 

  73. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med. Jan 23 1992;326(4):231–235.

    Google Scholar 

  74. Wise J. Southern Africa is moving swiftly to combat the threat of XDR-TB. Bull World Health Organ. Dec 2006;84(12):924–925.

    Google Scholar 

  75. Lobato MN, Hopewell PC. Mycobacterium tuberculosis infection after travel to or contact with visitors from countries with a high prevalence of tuberculosis. Am J Respir Crit Care Med. Dec 1998;158(6):1871–1875.

    Google Scholar 

  76. Cobelens FG, van Deutekom H, Draayer-Jansen IW, et al. Association of tuberculin sensitivity in Dutch adults with history of travel to areas of with a high incidence of tuberculosis. Clin Infect Dis. Aug 1 2001;33(3):300–304.

    Google Scholar 

  77. Driver CR, Valway SE, Morgan WM, Onorato IM, Castro KG. Transmission of Mycobacterium tuberculosis associated with air travel. JAMA. Oct 5 1994;272(13):1031–1035.

    Google Scholar 

  78. Rieder HL. Risk of travel-associated tuberculosis. Clin Infect Dis. Oct 15 2001;33(8):1393–1396.

    Google Scholar 

  79. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Adv Tuberc Res. 1970;17:28–106.

    Google Scholar 

  80. Horsburgh CR, Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med. May 13 2004;350(20):2060–2067.

    Google Scholar 

  81. Reichman LB, O’Day R. Tuberculous infection in a large urban population. Am Rev Respir Dis. Apr 1978;117(4):705–712.

    Google Scholar 

  82. Narain R, Nair SS, Chandrasekhar P, Rao GR. Problems connected with estimating the incidence of tuberculosis infection. Bull World Health Organ. 1966;34(4):605–622.

    PubMed  CAS  Google Scholar 

  83. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. Feb 1974;99(2):131–138.

    Google Scholar 

  84. Long NH, Diwan VK, Winkvist A. Difference in symptoms suggesting pulmonary tuberculosis among men and women. J Clin Epidemiol. Feb 2002;55(2):115–120.

    Google Scholar 

  85. Thorson A, Hoa NP, Long NH, Allebeck P, Diwan VK. Do women with tuberculosis have a lower likelihood of getting diagnosed? Prevalence and case detection of sputum smear positive pulmonary TB, a population-based study from Vietnam. J Clin Epidemiol. Apr 2004;57(4):398–402.

    Google Scholar 

  86. Comstock GW, Livesay VT, Woolpert SF. Evaluation of BCG vaccination among Puerto Rican children. Am J Public Health. Mar 1974;64(3):283–291.

    Google Scholar 

  87. Horwitz O, Wilbek E, Erickson PA. Epidemiological basis of tuberculosis eradication. 10 Longitudinal studies on the risk of tuberculosis in the general population of a low-prevalence area. Bull World Health Organ. 1969;41:95–113.

    PubMed  CAS  Google Scholar 

  88. Rieder HL. Tuberculosis in an Indochinese refugee camp: epidemiology, management and therapeutic results. Tubercle. Sep 1985;66(3):179–186.

    Google Scholar 

  89. Tuberculosis Prevention Trial M. Trial of BCG vaccines in South India for tuberculosis prevention. Indian J Med Res. 1980;72(Suppl.):1–74.

    Google Scholar 

  90. Comstock GW, Edwards PQ. The competing risks of tuberculosis and hepatitis for adult tuberculin reactors. Am Rev Respir Dis. May 1975;111(5):573–577.

    Google Scholar 

  91. Chan-Yeung M, Noertjojo K, Chan SL, Tam CM. Sex differences in tuberculosis in Hong Kong. Int J Tuberc Lung Dis. Jan 2002;6(1): 11–18.

    Google Scholar 

  92. Hurtado AM, Hill KR, Rosenblatt W, Bender J, Scharmen T. Longitudinal study of tuberculosis outcomes among immunologically naive Ache natives of Paraguay. Am J Phys Anthropol. Jun 2003;121(2):134–150.

    Google Scholar 

  93. Watkins RE, Plant AJ. Does smoking explain sex differences in the global tuberculosis epidemic? Epidemiol Infect. Apr 2006;134(2):333–339.

    Google Scholar 

  94. Lurie MB. Native and acquired resistance to tuberculosis. Am J Med. Nov 1950;9(5):591–610.

    Google Scholar 

  95. Lurie M. Resistance to Tuberculosis: Experimental Studies in Native and Acquired Defensive Mechanisms. Cambridge, MA: Harvard University Press; 1984.

    Google Scholar 

  96. Bellamy R. Susceptibility to mycobacterial infections: the importance of host genetics. Genes Immun. Jan 2003;4(1):4–11.

    Google Scholar 

  97. Fernando SL, Britton WJ. Genetic susceptibility to mycobacterial disease in humans. Immunol Cell Biol. Apr 2006;84(2): 125–137.

    Google Scholar 

  98. Puffer RR. Familial Susceptibility to Tuberculosis. Cambridge, MA: Harvard University Press; 1944.

    Google Scholar 

  99. Comstock GW. Tuberculosis in twins: a re-analysis of the Prophit survey. Am Rev Respir Dis. Apr 1978;117(4):621–624.

    Google Scholar 

  100. Overfield T, Klauber MR. Prevalence tuberculosis in Eskimos having blood group B gene. Hum Biol. Feb 1980;52(1):87–92.

    Google Scholar 

  101. Horwitz O, Comstock GW. What is a case of tuberculosis? The tuberculosis case spectrum in eight countries evaluated from 1235 case histories and roentgenograms. Int J Epidemiol. Summer 1973;2(2): 145–152.

    Google Scholar 

  102. Stead WW, Senner JW, Reddick WT, Lofgren JP. Racial differences in susceptibility to infection by Mycobacterium tuberculosis. N Engl J Med. Feb 15 1990;322(7): 422–427.

    Google Scholar 

  103. Creatore MI, Lam M, Wobeser WL. Patterns of tuberculosis risk over time among recent immigrants to Ontario, Canada. Int J Tuberc Lung Dis. Jun 2005;9(6):667–672.

    Google Scholar 

  104. Farah MG, Meyer HE, Selmer R, Heldal E, Bjune G. Long-term risk of tuberculosis among immigrants in Norway. Int J Epidemiol. Mar 31 2005;34(5):1005–1011.

    Google Scholar 

  105. Carvalho AC, Saleri N, El-Hamad I, et al. Completion of screening for latent tuberculosis infection among immigrants. Epidemiol Infect. Feb 2005;133(1):179–185.

    Google Scholar 

  106. Pang SC, Harrison RH, Brearley J, Jegathesan V, Clayton AS. Tuberculosis surveillance in immigrants through health undertakings in Western Australia. Int J Tuberc Lung Dis. Mar 2000;4(3):232–236.

    Google Scholar 

  107. Lillebaek T, Andersen AB, Dirksen A, Smith E, Skovgaard LT, Kok-Jensen A. Persistent high incidence of tuberculosis in immigrants in a low-incidence country. Emerg Infect Dis. Jul 2002;8(7):679–684.

    Google Scholar 

  108. Gershon RR, Vlahov D, Escamilla-Cejudo JA, et al. Tuberculosis risk in funeral home employees. J Occup Environ Med. May 1998;40(5):497–503.

    Google Scholar 

  109. Seidler A, Nienhaus A, Diel R. Review of epidemiological studies on the occupational risk of tuberculosis in low-incidence areas. Respiration. Jul–Aug 2005;72(4):431–446.

    Google Scholar 

  110. Cook S, Maw KL, Munsiff SS, Fujiwara PI, Frieden TR. Prevalence of tuberculin skin test positivity and conversions among healthcare workers in New York City during 1994–2001. Infect Control Hosp Epidemiol. Nov 2003;24(11):807–813.

    Google Scholar 

  111. Dimitrova B, Hutchings A, Atun R, et al. Increased risk of tuberculosis among health care workers in Samara Oblast, Russia: analysis of notification data. Int J Tuberc Lung Dis. Jan 2005;9(1):43–48.

    Google Scholar 

  112. Larsen NM, Biddle CL, Sotir MJ, White N, Parrott P, Blumberg HM. Risk of tuberculin skin test conversion among health care workers: occupational versus community exposure and infection. Clin Infect Dis. Oct 1 2002;35(7):796–801.

    Google Scholar 

  113. Chan JC, Tabak JI. Risk of tuberculous infection among house staff in an urban teaching hospital. South Med J. Sep 1985;78(9):1061–1064.

    Google Scholar 

  114. Hosoglu S, Tanrikulu AC, Dagli C, Akalin S. Tuberculosis among health care workers in a short working period. Am J Infect Control. Feb 2005;33(1):23–26.

    Google Scholar 

  115. Hnizdo E, Murray J. Risk of pulmonary tuberculosis relative to silicosis and exposure to silica dust in South African gold miners. Occup Environ Med. Jul 1998;55(7):496–502.

    Google Scholar 

  116. Chen GX, Burnett CA, Cameron LL, et al. Tuberculosis mortality and silica exposure: a case-control study based on a national mortality database for the years 1983–1992. Int J Occup Environ Health. Jul 1997;3(3):163–170.

    Google Scholar 

  117. Schepers GW, Delahant AG, Fear EJ, Schmidt JG. The biological action of Degussa submicron amorphous silica dust (Dow Corning Silica). IV. Studies on guinea pigs infected with tuberculosis. AMA Arch Ind Health. Nov 1957;16(5):363–379.

    Google Scholar 

  118. Solomon A, Rees D, Felix M, Venter E. Silicosis and tuberculosis: a proposed radiographic classification of tuberculosis to accompany the ILO international classification of radiographs of pneumoconioses. Int J Occup Environ Health. Jul–Sep 2000;6(3):215–219.

    Google Scholar 

  119. Corbett EL, Churchyard GJ, Clayton TC, et al. HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners. AIDS. Dec 1 2000;14(17):2759–2768.

    Google Scholar 

  120. Corbett EL, Churchyard GJ, Clayton T, et al. Risk factors for pulmonary mycobacterial disease in South African gold miners. A case-control study. Am J Respir Crit Care Med. Jan 1999;159(1):94–99.

    Google Scholar 

  121. Kuemmerer JM, Comstock GW. Sociologic concomitants of tuberculin sensitivity. Am Rev Respir Dis. Nov 1967;96(5):885–892.

    Google Scholar 

  122. Barr RG, Diez-Roux AV, Knirsch CA, Pablos-Mendez A. Neighborhood poverty and the resurgence of tuberculosis in New York City, 1984–1992. Am J Public Health. Sep 2001;91(9):1487–1493.

    Google Scholar 

  123. Doll R, Hill AB. Lung cancer and other causes of death in relation to smoking; a second report on the mortality of British doctors. Br Med J. Nov 10 1956;12(5001):1071–1081.

    Google Scholar 

  124. Lowe CR. An association between smoking and respiratory tuberculosis. Br Med J. Nov 10 1956;12(5001):1081–1086.

    Google Scholar 

  125. den Boon S, van Lill SW, Borgdorff MW, et al. Association between smoking and tuberculosis infection: a population survey in a high tuberculosis incidence area. Thorax. Jul 2005;60(7):555–557.

    Google Scholar 

  126. Leung CC, Li T, Lam TH, et al. Smoking and tuberculosis among the elderly in Hong Kong. Am J Respir Crit Care Med. Nov 1 2004;170(9):1027–1033.

    Google Scholar 

  127. Gajalakshmi V, Peto R, Kanaka TS, Jha P. Smoking and mortality from tuberculosis and other diseases in India: retrospective study of 43,000 adult male deaths and 35,000 controls. Lancet. Aug 16 2003;362(9383):507–515.

    Google Scholar 

  128. Bothamley GH. Smoking and tuberculosis: a chance or causal association? Thorax. Jul 2005;60(7):527–528.

    Google Scholar 

  129. Getz HR, Long ER, Henderson HJ. A study of the relation of nutrition to the development of tuberculosis; influence of ascorbic acid and vitamin A. Am Rev Tuberc. Oct 1951;64(4):381–393.

    Google Scholar 

  130. Rwangabwoba JM, Fischman H, Semba RD. Serum vitamin A levels during tuberculosis and human immunodeficiency virus infection. Int J Tuberc Lung Dis. Sep 1998;2(9):771–773.

    Google Scholar 

  131. Chan TY. Seasonal variations in vitamin-D status and the incidence of tuberculosis in different countries. Respiration. 1999;66(2):196.

    Article  PubMed  CAS  Google Scholar 

  132. Ustianowski A, Shaffer R, Collin S, Wilkinson RJ, Davidson RN. Prevalence and associations of vitamin D deficiency in foreign-born persons with tuberculosis in London. J Infect. Jun 2005;50(5):432–437.

    Google Scholar 

  133. Douglas AS, Strachan DP, Maxwell JD. Seasonality of tuberculosis: the reverse of other respiratory diseases in the UK. Thorax. Sep 1996;51(9):944–946.

    Google Scholar 

  134. Kielmann AA, Uberoi IS, Chandra RK, Mehra VL. The effect of nutritional status on immune capacity and immune responses in preschool children in a rural community in India. Bull World Health Organ. 1976;54(5):477–483.

    PubMed  CAS  Google Scholar 

  135. Range N, Changalucha J, Krarup H, Magnussen P, Andersen AB, Friis H. The effect of multi-vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two-by-two factorial trial in Mwanza, Tanzania. Br J Nutr. Apr 2006;95(4):762–770.

    Google Scholar 

  136. Range N, Andersen AB, Magnussen P, Mugomela A, Friis H. The effect of micronutrient supplementation on treatment outcome in patients with pulmonary tuberculosis: a randomized controlled trial in Mwanza, Tanzania. Trop Med Int Health. Sep 2005;10(9):826–832.

    Google Scholar 

  137. Comstock GW. Variability of tuberculosis trends in a time of resurgence. Clin Infect Dis. Dec 1994;19(6):1015–1022.

    Google Scholar 

  138. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. Mar 2 1989;320(9):545–550.

    Google Scholar 

  139. Narain JP, Raviglione MC, Kochi A. HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. Tuber Lung Dis. Dec 1992;73(6):311–321.

    Google Scholar 

  140. Hopewell PC. Impact of human immunodeficiency virus infection on the epidemiology, clinical features, management, and control of tuberculosis. Clin Infect Dis. Sep 1992;15(3):540–547.

    Google Scholar 

  141. Nachega J, Coetzee J, Adendorff T, et al. Tuberculosis active case-finding in a mother-to-child HIV transmission prevention programme in Soweto, South Africa. AIDS. Jun 13 2003;17(9):1398–1400.

    Google Scholar 

  142. Braun MM, Badi N, Ryder RW, et al. A retrospective cohort study of the risk of tuberculosis among women of childbearing age with HIV infection in Zaire. Am Rev Respir Dis. Mar 1991;143(3):501–504.

    Google Scholar 

  143. Allen S, Batungwanayo J, Kerlikowske K, et al. Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. Am Rev Respir Dis. Dec 1992;146(6):1439–1444.

    Google Scholar 

  144. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis. Jan 15 2005;191(2):150–158.

    Google Scholar 

  145. Kimerling ME, Schuchter J, Chanthol E, et al. Prevalence of pulmonary tuberculosis among HIV-infected persons in a home care program in Phnom Penh, Cambodia. Int J Tuberc Lung Dis. Nov 2002;6(11):988–994.

    Google Scholar 

  146. Ruxin J, Paluzzi JE, Wilson PA, Tozan Y, Kruk M, Teklehaimanot A. Emerging consensus in HIV/AIDS, malaria, tuberculosis, and access to essential medicines. Lancet. Feb 12–18 2005;365(9459):618–621.

    Google Scholar 

  147. UNAIDS. 2004 Report on the Global AIDS Epidemic. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2004.

    Google Scholar 

  148. Robinson DB, Comstock GW. Tuberculosis in a small semi-rural county. Public Health Rep. Mar–Apr 1992;107(2):179–182.

    Google Scholar 

  149. Radhakrishna S, Frieden TR, Subramani R. Association of initial tuberculin sensitivity, age and sex with the incidence of tuberculosis in south India: a 15-year follow-up. Int J Tuberc Lung Dis. Nov 2003;7(11):1083–1091.

    Google Scholar 

  150. Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the United States among HIV-infected persons. The Pulmonary Complications of HIV Infection Study Group. Ann Intern Med. Jan 15 1997;126(2):123–132.

    Google Scholar 

  151. MMWR. Human tuberculosis caused by Mycobacterium bovis—New York City, 2001–2004. MMWR Morb Mortal Wkly Rep. Jun 24 2005;52(24):605–608.

    Google Scholar 

  152. Myers JA. Tuberculosis: A Half Century of Study and Conquest. St. Louis: Warren H. Green; 1970.

    Google Scholar 

  153. Sultan L, Nyka W, Mills C, O’Grady F, Wells W, Riley RL. Tuberculosis disseminators. A study of the variability of aerial infectivity of tuberculous patients. Am Rev Respir Dis. Sep 1960;82:358–369.

    Google Scholar 

  154. Keijman J, Tjhie J, Olde Damink S, Alink M. Unusual nosocomial transmission of Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis. Nov 2001;20(11):808–809.

    Google Scholar 

  155. Chaisson RE, McAvinue S. Control of tuberculosis during aerosol therapy administration. Respir Care. Sep 1991;36(9): 1017–1025.

    Google Scholar 

  156. Sterling TR, Pope DS, Bishai WR, Harrington S, Gershon RR, Chaisson RE. Transmission of Mycobacterium tuberculosis from a cadaver to an embalmer. N Engl J Med. Jan 27 2000;342(4):246–248.

    Google Scholar 

  157. Lauzardo M, Lee P, Duncan H, Hale Y. Transmission of Mycobacterium tuberculosis to a funeral director during routine embalming. Chest. Feb 2001;119(2):640–642.

    Google Scholar 

  158. Lundgren R, Norrman E, Asberg I. Tuberculosis infection transmitted at autopsy. Tubercle. Jun 1987;68(2):147–150.

    Google Scholar 

  159. Kramer F, Sasse SA, Simms JC, Leedom JM. Primary cutaneous tuberculosis after a needlestick injury from a patient with AIDS and undiagnosed tuberculosis. Ann Intern Med. Oct 1 1993;119(7 Pt 1):594–595.

    Google Scholar 

  160. Oymak SF, Gulmez I, Demir R, Ozesmi M. Transmission of Mycobacterium tuberculosis by accidental needlestick. Respiration. 2000;67(6):696–697.

    Article  PubMed  CAS  Google Scholar 

  161. Smith JH. The hazard to pathologists from tuberculous specimens. Hum Pathol. Dec 1996;27(12):1251–1252.

    Google Scholar 

  162. Michele TM, Cronin WA, Graham NM, et al. Transmission of Mycobacterium tuberculosis by a fiberoptic bronchoscope. Identification by DNA fingerprinting. JAMA. Oct 1 1997;278(13): 1093–1095.

    Google Scholar 

  163. Culver DA, Gordon SM, Mehta AC. Infection control in the bronchoscopy suite: a review of outbreaks and guidelines for prevention. Am J Respir Crit Care Med. Apr 15 2003;167(8): 1050–1056.

    Google Scholar 

  164. Angus BJ, Yates M, Conlon C, Byren I. Cutaneous tuberculosis of the penis and sexual transmission of tuberculosis confirmed by molecular typing. Clin Infect Dis. Dec 1 2001;33(11):E132–E134.

    Google Scholar 

  165. Vergne I, Chua J, Singh SB, Deretic V. Cell biology of Mycobacterium tuberculosis phagosome. Annu Rev Cell Dev Biol. 2004;20:367–394.

    Article  PubMed  CAS  Google Scholar 

  166. Renshaw PS, Lightbody KL, Veverka V, et al. Structure and function of the complex formed by the tuberculosis virulence factors CFP-10 and ESAT-6. Embo J. Jul 20 2005;24(14):2491–2498.

    Google Scholar 

  167. Rengarajan J, Bloom BR, Rubin EJ. Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. Proc Natl Acad Sci U S A. Jun 7 2005;102(23):8327–8332.

    Google Scholar 

  168. Lillebaek T, Kok-Jensen A, Viskum K. Bacillarity at autopsy in pulmonary tuberculosis. Mycobacterium tuberculosis is often disseminated. Apmis. Sep 2002;110(9):625–629.

    Google Scholar 

  169. Verver S, Warren RM, Beyers N, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med. Jun 15 2005;171(12):1430–1435.

    Google Scholar 

  170. Cave MD, Eisenach KD, McDermott PF, Bates JH, Crawford JT. IS6110: conservation of sequence in the Mycobacterium tuberculosis complex and its utilization in DNA fingerprinting. Mol Cell Probes. Feb 1991;5(1):73–80.

    Google Scholar 

  171. Bishai WR, Graham NM, Harrington S, et al. Molecular and geographic patterns of tuberculosis transmission after 15 years of directly observed therapy. JAMA. Nov 18 1998;280(19):1679–1684.

    Google Scholar 

  172. Cronin WA, Golub JE, Lathan MJ, et al. Molecular epidemiology of tuberculosis in a low- to moderate-incidence state: are contact investigations enough? Emerg Infect Dis. Nov 2002;8(11): 1271–1279.

    Google Scholar 

  173. Lillebaek T, Dirksen A, Baess I, Strunge B, Thomsen VO, Andersen AB. Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. J Infect Dis. Feb 1 2002;185(3):401–404.

    Google Scholar 

  174. de Boer AS, Borgdorff MW, Vynnycky E, Sebek MM, van Soolingen D. Exogenous re-infection as a cause of recurrent tuberculosis in a low-incidence area. Int J Tuberc Lung Dis. Feb 2003;7(2): 145–152.

    Google Scholar 

  175. Jasmer RM, Bozeman L, Schwartzman K, et al. Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med. Dec 15 2004;170(12):1360–1366.

    Google Scholar 

  176. Alland D, Kalkut GE, Moss AR, et al. Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med. Jun 16 1994;330(24): 1710–1716.

    Google Scholar 

  177. Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N Engl J Med. Jun 16 1994;330(24):1703–1709.

    Google Scholar 

  178. van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med. Oct 14 1999;341(16):1174–1179.

    Google Scholar 

  179. Heimbeck J. Sur la vaccination preventive de la tuberculose par injection sous-cutanee de BCG chez les eleves-infirmieres de l’hopital Ulleval, a Oslo (Norvege). Ann Inst Pasteur. 1928;42:1229–1232.

    Google Scholar 

  180. Stead WW. Management of health care workers after inadvertent exposure to tuberculosis: a guide for the use of preventive therapy. Ann Intern Med. Jun 15 1995;122(12):906–912.

    Google Scholar 

  181. Fine PE, Small PM. Exogenous reinfection in tuberculosis. N Engl J Med. Oct 14 1999;341(16):1226–1227.

    Google Scholar 

  182. Small PM, Shafer RW, Hopewell PC, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med. Apr 22 1993;328(16): 1137–1144.

    Google Scholar 

  183. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet. Nov 17 2001;358(9294):1687–1693.

    Google Scholar 

  184. Sterling TR, Dorman SE, Chaisson RE, et al. Human immunodeficiency virus-seronegative adults with extrapulmonary tuberculosis have abnormal innate immune responses. Clin Infect Dis. Oct 1 2001;33(7):976–982.

    Google Scholar 

  185. Dorman SE, Picard C, Lammas D, et al. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet. Dec 11–17 2004;364(9451):2113–2121.

    Google Scholar 

  186. Yang Z, Kong Y, Wilson F, et al. Identification of risk factors for extrapulmonary tuberculosis. Clin Infect Dis. Jan 15 2004;38(2):199–205.

    Google Scholar 

  187. Ferebee SH. An epidemiological model of tuberculosis in the United States. Bull Nat Tuberc Assoc. 1967;53:4–7.

    Google Scholar 

  188. Addington WW, Albert RK, Bass JB, Jr., et al. Non-drug issues related to the treatment of tuberculosis. Chest. Feb 1985;87(2 Suppl):125S–127S.

    Google Scholar 

  189. Garner JS. Guideline for isolation precautions in hospitals. Part I. Evolution of isolation practices, Hospital Infection Control Practices Advisory Committee. Am J Infect Control. Feb 1996;24(1): 24–31.

    Google Scholar 

  190. Mindes P. Tuberculosis quarantine: a review of legal issues in Ohio and other states. J Law Health. 1995;10(2): 403–428.

    PubMed  Google Scholar 

  191. Gasner MR, Maw KL, Feldman GE, Fujiwara PI, Frieden TR. The use of legal action in New York City to ensure treatment of tuberculosis. N Engl J Med. Feb 4 1999;340(5):359–366.

    Google Scholar 

  192. Coker R. Just coercion? Detention of nonadherent tuberculosis patients. Ann N Y Acad Sci. Dec 2001;953:216–223.

    Google Scholar 

  193. WHO. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2006 (WHO HTM/TB/2006.362).

    Google Scholar 

  194. Grzybowski S. Technical and operational appraisal of tuberculosis case-finding methods, in: II. Regional Seminar of Tuberculosis, Scientific Publ. No. 265. Paper presented at: Washington, DC: Pan American Health Organization; 1973.

    Google Scholar 

  195. Golub JE, Mohan CI, Comstock GW, Chaisson RE. Active case finding of tuberculosis: historical perspective and future prospects. Int J Tuberc Lung Dis. Nov 2005;9(11):1183–1203.

    Google Scholar 

  196. Survey of patients presenting to the government chest service in Hong Kong and the effects of active tuberculosis case-finding by publicity campaigns. Hong Kong Chest Service/British Medical Research Council. Tubercle. 1984;65:173–184.

    Google Scholar 

  197. Desormeaux J, Johnson MP, Coberly JS, et al. Widespread HIV counseling and testing linked to a community-based tuberculosis control program in a high-risk population. Bull Pan Am Health Organ. Mar 1996;30(1):1–8.

    Google Scholar 

  198. Kali PN, Martinson NA, Chaisson RE, Gray GE, McIntyre J. Prevalence of active tuberculosis in HIV infected women at antinatal VCT in PMTCT programme in Soweto, South Africa. Paper presented at: XV International AIDS Conference, 2004.

    Google Scholar 

  199. Zachariah R, Spielmann MP, Harries AD, et al. Passive versus active tuberculosis case finding and isoniazid preventive therapy among household contacts in a rural district of Malawi. Int J Tuberc Lung Dis. Nov 2003;7(11):1033–1039.

    Google Scholar 

  200. WHO. Treatment of Tuberculosis. 3rd ed. Geneva: World Health Organization; 2003.

    Google Scholar 

  201. Fox W. Compliance of patients and physicians: experience and lessons from tuberculosis-I. Br Med J (Clin Res Ed). Jul 2 1983;287(6384):33–35.

    Google Scholar 

  202. Kaona FA, Tuba M, Siziya S, Sikaona L. An assessment of factors contributing to treatment adherence and knowledge of TB transmission among patients on TB treatment. BMC Public Health. Dec 29 2004;4(1):68.

    Google Scholar 

  203. van der Werf TS, Dade GK, van der Mark TW. Patient compliance with tuberculosis treatment in Ghana: factors influencing adherence to therapy in a rural service programme. Tubercle. Dec 1990;71(4):247–252.

    Google Scholar 

  204. Farmer P, Robin S, Ramilus SL, Kim JY. Tuberculosis, poverty, and "compliance": lessons from rural Haiti. Semin Respir Infect. Dec 1991;6(4):254–260.

    Google Scholar 

  205. Comolet TM, Rakotomalala R, Rajaonarioa H. Factors determining compliance with tuberculosis treatment in an urban environment, Tamatave, Madagascar. Int J Tuberc Lung Dis. Nov 1998;2(11): 891–897.

    Google Scholar 

  206. Naing NN, D’Este C, Isa AR, Salleh R, Bakar N, Mahmod MR. Factors contributing to poor compliance with anti-TB treatment among tuberculosis patients. Southeast Asian J Trop Med Public Health. Jun 2001;32(2):369–382.

    Google Scholar 

  207. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis. Jan 1998;2(1):10–15.

    Google Scholar 

  208. Mathur ML, Khatri PK, Base CS. Drug resistance in tuberculosis patients in Jodhpur district. Indian J Med Sci. Feb 2000;54(2): 55–58.

    Google Scholar 

  209. Timperi R, Han LL, Sloutsky A, et al. Drug resistance profiles of Mycobacterium tuberculosis isolates: five years’ experience and insight into treatment strategies for MDR-TB in Lima, Peru. Int J Tuberc Lung Dis. Feb 2005;9(2):175–180.

    Google Scholar 

  210. Ruddy M, Balabanova Y, Graham C, et al. Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia. Thorax. Feb 2005;60(2):130–135.

    Google Scholar 

  211. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR, Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. Feb 25 1993;328(8):527–532.

    Google Scholar 

  212. Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis. Mar 2004;8(3):361–368.

    Google Scholar 

  213. Yew WW. Directly observed therapy, short-course: the best way to prevent multidrug-resistant tuberculosis. Chemotherapy. 1999;45 Suppl 2:26–33.

    Article  Google Scholar 

  214. Kam KM, Yip CW. Surveillance of Mycobacterium tuberculosis drug resistance in Hong Kong, 1986–1999, after the implementation of directly observed treatment. Int J Tuberc Lung Dis. Sep 2001;5(9):815–823.

    Google Scholar 

  215. Pope DS, Chaisson RE. TB treatment: as simple as DOT? Int J Tuberc Lung Dis. Jul 2003;7(7):611–615.

    Google Scholar 

  216. Chaulk CP, Pope DS. The Baltimore City Health Department program of directly observed therapy for tuberculosis. Clin Chest Med. Mar 1997;18(1):149–154.

    Google Scholar 

  217. Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. JAMA. Sep 27 1995;274(12):945–951.

    Google Scholar 

  218. Mathew A, Binks C, Kuruvilla J, Davies PD. A comparison of two methods of undertaking directly observed therapy in a rural indian setting. Int J Tuberc Lung Dis. Jan 2005;9(1):69–74.

    Google Scholar 

  219. Volmink J, Matchaba P, Garner P. Directly observed therapy and treatment adherence. Lancet. Apr 15 2000;355(9212):1345–1350.

    Google Scholar 

  220. Curry FJ. District clinics for out patient treatment of tuberculous problem patients. Dis Chest. Nov 1964;46:524–530.

    Google Scholar 

  221. WHO. What is DOTS? A Guide to Understanding the WHO Recommended Strategy Known as DOTS. Geneva: World Health Organization; 1999.

    Google Scholar 

  222. WHO. An Expanded DOTS Framework for Effective Tuberculosis Control. October 10, 2005; http://www.who.int/tb/dots/framework/en/index.html

  223. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis. Apr 1991;143(4 Pt 1):700–706.

    Google Scholar 

  224. Singapore. Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore. The results up to 30 months. Am Rev Respir Dis. Nov 1977;116(5):807–820.

    Google Scholar 

  225. Ogden J, Walt G, Lush L. The politics of ‘branding’ in policy transfer: the case of DOTS for tuberculosis control. Soc Sci Med. Jul 2003;57(1):179–188.

    Google Scholar 

  226. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City—turning the tide. N Engl J Med. Jul 27 1995;333(4):229–233.

    Google Scholar 

  227. Comstock GW, Woolpert SF. Preventive therapy, in: The Mycobacteria: A Sourcebook, GP Kubica, LG Wayne, eds. New York: Marcel Dekker; 1984.

    Google Scholar 

  228. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD, Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet. Jul 31 1993;342(8866):268–272.

    Google Scholar 

  229. Committee on Prophylaxis. Efficacy of various durations of isonizaid preventive therapy for tuberculosis: five years of follow-up in the IUAT Trial. Bull World Health Organ. 1982;60:555–564.

    Google Scholar 

  230. Comstock GW, Ferebee SH. How much isoniazid is needed for prophylaxis? Am Rev Respir Dis. May 1970;101(5):780–782.

    Google Scholar 

  231. Ferebee SH, Hopwood L, Palmer CE. Studies on prevention of experimental tuberculosis with isoniazid. II. Effects of different dosage regimens. Am Rev Tuberc. Dec 1956;74(6):917–939.

    Google Scholar 

  232. Comstock GW, Baum C, Snider DE, Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis. May 1979;119(5):827–830.

    Google Scholar 

  233. Graham NM, Chaisson RE. Tuberculosis and HIV infection: epidemiology, pathogenesis, and clinical aspects. Ann Allergy. Nov 1993;71(5):421–428; quiz 428–433.

    Google Scholar 

  234. Fitzgerald DW, Desvarieux M, Severe P, Joseph P, Johnson WD, Jr., Pape JW. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet. Oct 28 2000;356(9240):1470–1474.

    Google Scholar 

  235. Halsey NA, Coberly JS, Desormeaux J, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet. Mar 14 1998;351(9105): 786–792.

    Google Scholar 

  236. Gordin F, Chaisson RE, Matts JP, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA. Mar 15 2000;283(11):1445–1450.

    Google Scholar 

  237. Jasmer RM, Saukkonen JJ, Blumberg HM, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med. Oct 15 2002;137(8):640–647.

    Google Scholar 

  238. MMWR. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection—United States, 2003. MMWR Morb Mortal Wkly Rep. Aug 8 2003;52(31): 735–739.

    Google Scholar 

  239. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2004(1):CD000171.

    Google Scholar 

  240. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA. Mar 2 1994;271(9):698–702.

    Google Scholar 

  241. Comstock GW. Identification of an effective vaccine against tuberculosis. Am Rev Respir Dis. Aug 1988;138(2):479–480.

    Google Scholar 

  242. Ten Dam HG. BCG vaccination, in: Tuberculosis: A Comprehensive International Approach. LB Reichman, ES Hershfield eds. New York: Marcel Dekker; 1993.

    Google Scholar 

  243. Comstock GW. Field trials of tuberculosis vaccines: how could we have done them better? Control Clin Trials. Aug 1994;15(4): 247–276.

    Google Scholar 

  244. Behr MA. Comparative genomics of BCG vaccines. Tuberculosis (Edinb). 2001;81(1–2):165–168.

    Article  CAS  Google Scholar 

  245. MMWR. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR Recomm Rep. Apr 26 1996;45(RR-4):1–18.

    Google Scholar 

  246. Narain R, Vallishayee RS. BCG vaccination of tuberculosis patients and of strong reactors to tuberculin. Bull Int Union Tuberc. 1976;51(1):243–246.

    PubMed  CAS  Google Scholar 

  247. Dourado I, Rios MH, Pereira SM, et al. Rates of adverse reactions to first and second doses of BCG vaccination: results of a large community trial in Brazilian schoolchildren. Int J Tuberc Lung Dis. Apr 2003;7(4):399–402.

    Google Scholar 

  248. Milstien JB, Gibson JJ. Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety. Bull World Health Organ. 1990;68(1):93–108.

    PubMed  CAS  Google Scholar 

  249. Lotte A, Wasz-Hockert O, Poisson N, et al. Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuberc Lung Dis. Jun 1988;63(2):47–59.

    Google Scholar 

  250. Riley RL, Wells WF, Mills CC, Nyka W, McLean RL. Air hygiene in tuberculosis: quantitative studies of infectivity and control in a pilot ward. Am Rev Tuberc. Mar 1957;75(3):420–431.

    Google Scholar 

  251. Espinal MA, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med. Apr 26 2001;344(17):1294–1303.

    Google Scholar 

  252. Garcia-Garcia ML, Jimenez-Corona ME, Ponce-de-Leon A, et al. Mycobacterium tuberculosis drug resistance in a suburban community in southern Mexico. Int J Tuberc Lung Dis. Dec 2000;4(12 Suppl 2):S168–S170.

    Google Scholar 

  253. Miah MR, Ali MS, Saleh AA, Sattar H. Primary drug resistance pattern of Mycobacterium tuberculosis in Dhaka, Bangladesh. Bangladesh Med Res Counc Bull. Aug 2000;26(2):33–40.

    Google Scholar 

  254. Iseman MD. Treatment and implications of multidrug-resistant tuberculosis for the 21st century. Chemotherapy. 1999;45 Suppl 2:34–40.

    Article  Google Scholar 

  255. Cohen J. Global health. Public-private partnerships proliferate. Science. Jan 13 2006;311(5758):167.

    Google Scholar 

  256. Cohen J. Global health. The new world of global health. Science. Jan 13 2006;311(5758):162–167.

    Google Scholar 

  257. WHO. The Global Plan to Stop TB 2006–2015. Stop TB Partnership and World Health Organization (WHO/HTM/STB/2006.35). 2006.

    Google Scholar 

Suggested Readings

  • American Thoracic Society Documents. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603–662.

    Google Scholar 

  • Centers for Disease Control and Prevention. A strategic plan for the elimination of tuberculosis in the United States, Morb Mortal Wkly Rep. 1989;38(Suppl no. S-3):1–25.

    Google Scholar 

  • Daniel TM. Captain of Death: The Story of Tuberculosis. Rochester, NY: University of Rochester Press; 1997.

    Google Scholar 

  • Edwards PQ, Edwards LB. Story of the tuberculin test from an epidemiological viewpoint. Am Rev Respir Dis. 1960;81(1):Part 2.

    Google Scholar 

  • Enarson DA, Rieder HL, Arnadottir T, Tribucq A. Tuberculosis Guide for Low Income Countries. 4th ed. Frankfurt, Germany: International Union Against Tuberculosis and Lung Disease; 1994.

    Google Scholar 

  • Frost WH. How much control of tuberculosis? Am J Public Health. 1937;27:759–766.

    Article  CAS  Google Scholar 

  • Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res. 1970;17:28–106.

    Google Scholar 

  • Iseman MD. A Clinician’s Guide to Tuberculosis. Philadelphia, PA: Lippincott Williams & Wilkins; 2000.

    Google Scholar 

  • O’Reilly LM, Daborn CJ. The epidemiology of Mycobacterium bovis infections in animals and man: a review. Tuber Lung Dis. 1995;76(Suppl. 1): 1–46.

    Article  PubMed  Google Scholar 

  • Rieder HL. Epidemiologic Basis of Tuberculosis Control. Paris: International Union Against Tuberculosis and Lung Disease; 1999.

    Google Scholar 

  • Ryan F. The Forgotten Plague: How the Battle Against Tuberculosis Was Won—And Lost. Boston, MA: Little, Bwon and company, 1992.

    Google Scholar 

  • Sumartojo E. When tuberculosis treatment fails. A social behavioral account of patient adherence. Am Rev Respir Dis. 1993;147:1311–1320.

    PubMed  CAS  Google Scholar 

  • Thompson NJ, Glassroth JH, Snider DE, Jr., et al., The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis. 1979;119:587–597.

    PubMed  CAS  Google Scholar 

  • WHO. Toman’s Tuberculosis: Case Detection, Treatment, and Monitoring—Questions and Answers. T. Frieden, ed. 2nd ed. Geneva; 2004.

    Google Scholar 

  • WHO Stop TB Partnership. The Gobal Plan to Stop TB, 2006–2015. Geneva; 2006.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Portland VA Medical Center, Portland, Oregon 97239, USA

    Diana S. Pope

  2. Center for Tuberculosis Research, Johns Hopkins University, 1550 Orleans Street, Baltimore, Maryland 21231, USA

    Richard E. Chaisson

  3. Bloomberg School of Public Health, George W. Comstock Center for Public Health Research and Prevention, The Johns Hopkins University, Box 2067, Hagerstown, Maryland 21742-2067, USA

    George W. Comstock

Authors
  1. Diana S. Pope
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard E. Chaisson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. George W. Comstock
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Diana S. Pope .

Editor information

Editors and Affiliations

  1. Rollins School of Public Health, Emory University, Clifton Road NE., 1518, Atlanta, 30322, U.S.A.

    Philip S. Brachman

  2. College of Medicine, Office of Faculty Affairs, Drexel University, Race Street 1505, Philadelphia, 19102, U.S.A.

    Elias Abrutyn

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Pope, D.S., Chaisson, R.E., Comstock, G.W. (2009). Tuberculosis. In: Brachman, P., Abrutyn, E. (eds) Bacterial Infections of Humans. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-09843-2_40

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-09843-2_40

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-09842-5

  • Online ISBN: 978-0-387-09843-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation